The effect of controlled expression of VEGF by transduced myoblasts in a cardiac patch on vascularization in a mouse model of myocardial infarction
Source abstract
Abstract
Key requirements for cardiac tissue engineering include the maintenance of cell viability and function and the establishment of a perfusable vascular network in millimeters thick and compact cardiac constructs upon implantation. We investigated if these requirements can be met by providing an intrinsic vascularization stimulus (via sustained action of VEGF secreted at a controlled rate by transduced myoblasts) to a cardiac patch engineered under conditions of effective oxygen supply (via medium flow through channeled elastomeric scaffolds seeded with neonatal cardiomyocytes). We demonstrate that this combined approach resulted in increased viability, vascularization and functionality of the cardiac patch. After implantation in a mouse model of myocardial infarction, VEGF-expressing patches displayed significantly improved engraftment, survival and differentiation of cardiomyocytes, leading to greatly enhanced contractility as compared to controls not expressing VEGF. Controlled VEGF expression also mediated the formation of mature vascular networks, both within the engineered patches and in the underlying ischemic myocardium. We propose that this combined cell-biomaterial approach can be a promising strategy to engineer cardiac patches with intrinsic and extrinsic vascularization potential.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Electrospun Nanofibers in Biomedical Applications · Congenital heart defects research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Evidence for cardiomyocyte renewal in humans10.1126/science.1164680 ↗
2. Tissue engineering of vascularized cardiac muscle from human embryonic stem cells10.1161/01.RES.0000257776.05673.ff ↗
3. Developing vasculature and stroma in engineered human myocardium10.1089/ten.tea.2010.0557 ↗
4. Proangiogenic scaffolds as functional templates for cardiac tissue engineering10.1073/pnas.1006442107 ↗
5. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue10.1073/pnas.0908381106 ↗
6. Composite scaffold provides a cell delivery platform for cardiovascular repair10.1073/pnas.1104619108 ↗
7. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts10.1038/nm1394 ↗
8. Cathepsin L is required for endothelial progenitor cell-induced neovascularization10.1038/nm1182 ↗
9. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces10.1161/hh0302.105722 ↗
10. Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters10.1016/j.cardiores.2005.11.005 ↗
11. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction10.1038/nm1391 ↗
12. Cardiac cell therapy trials: chronic myocardial infarction and congestive heart failure10.1007/s12265-008-9017-1 ↗
13. Challenges in cardiac tissue engineering10.1089/ten.teb.2009.0352 ↗
14. Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds10.1073/pnas.0407817101 ↗
15. Heart muscle engineering: an update on cardiac muscle replacement therapy10.1016/j.cardiores.2006.03.023 ↗
16. Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues10.1096/fj.05-4715fje ↗
17. Perfusion seeding of channeled elastomeric scaffolds with myocytes and endothelial cells for cardiac tissue engineering10.1002/btpr.337 ↗
18. Cardiac tissue engineering using perfusion bioreactor systems10.1038/nprot.2008.40 ↗
19. Scaffold stiffness affects the contractile function of three-dimensional engineered cardiac constructs10.1002/btpr.435 ↗
20. Angiogenesis in health and disease10.1038/nm0603-653 ↗
21. VEGF gene therapy: stimulating angiogenesis or angioma-genesis?10.1038/80430 ↗
22. VEGF gene delivery to myocardium: deleterious effects of unregulated expression10.1161/01.CIR.102.8.898 ↗
23. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation10.1016/S0735-1097(00)00522-2 ↗
24. VEGF gene delivery to muscle: potential role for vasculogenesis in adults10.1016/S1097-2765(00)80154-9 ↗
25. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis10.1172/JCI18420 ↗
26. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia10.1096/fj.06-6568fje ↗
27. High-throughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo10.1002/stem.291 ↗
28. FACS-purified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemia10.1111/j.1582-4934.2011.01308.x ↗
29. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy10.1083/jcb.125.6.1275 ↗
30. High-efficiency retroviral infection of primary myoblasts10.1007/BF02721371 ↗
31. Production of high-titer helper-free retroviruses by transient transfection10.1073/pnas.90.18.8392 ↗
32. Myoblast-mediated gene transfer for therapeutic angiogenesis10.1016/S0076-6879(02)46054-5 ↗
33. A biocompatible endothelial cell delivery system for in vitro tissue engineering10.3727/096368909X470919 ↗
34. Myocardial elastography at both high temporal and spatial resolution for the detection of infarcts10.1016/j.ultrasmedbio.2007.01.019 ↗
35. High-frame rate, full-view myocardial elastography with automated contour tracking in murine left ventricles in vivo10.1109/TUFFC.2008.633 ↗
36. A fast normalized cross-correlation calculation method for motion estimation10.1109/TUFFC.2010.1554 ↗
37. Axial strain calculation using a low-pass digital differentiator in ultrasound elastography10.1109/TUFFC.2004.1334844 ↗
38. Bioengineering heart muscle: a paradigm for regenerative medicine10.1146/annurev-bioeng-071910-124701 ↗
39. Biomimetic platforms for human stem cell research10.1016/j.stem.2011.02.014 ↗
40. Prevascularization of cardiac patch on the omentum improves its therapeutic outcome10.1073/pnas.0812242106 ↗
41. Vascularized atrial tissue patch cardiomyoplasty with omentopexy improves cardiac performance after myocardial infarction10.1016/j.athoracsur.2011.05.054 ↗
42. Transplantation of a tissue-engineered human vascularized cardiac muscle10.1089/ten.tea.2009.0130 ↗
43. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor10.1038/labinvest.3780013 ↗
44. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB10.1096/fj.11-197400 ↗
45. Bioactive scaffolds for engineering vascularized cardiac tissues10.1002/mabi.201000202 ↗
46. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy10.1093/emboj/21.8.1939 ↗
47. Critical role of microenvironmental factors in angiogenesis10.1007/s11883-005-0011-7 ↗
48. Side effects of retroviral gene transfer into hematopoietic stem cells10.1182/blood-2002-07-2314 ↗
49. In vivo assessment of the electrophysiological integration and arrhythmogenic risk of myocardial cell transplantation strategies10.1002/stem.545 ↗
50. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation10.1161/CIRCULATIONAHA.107.734103 ↗
51. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy10.1172/JCI37630 ↗
52. Physiological promoters reduce the genotoxic risk of integrating gene vectors10.1038/mt.2008.5 ↗
53. Cultured and freshly isolated adipose tissue-derived cells: fat years for cardiac stem cell therapy10.1093/eurheartj/ehp403 ↗
54. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction10.1016/j.jacc.2011.09.065 ↗
55. First in man transendocardial injection of autologous AdiPose-deRived StEm cells in patients with non RevaScularizable IschEmic myocardium (PRECISE)
56. Generation of human adult mesenchymal stromal/stem cells expressing defined xenogenic vascular endothelial growth factor levels by optimized transduction and flow cytometry purification10.1089/ten.tec.2011.0413 ↗